Antisense Oligonucleotides and RNA Interference - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 382

[218] Ho SP, Bao Y, Lesher T, Conklin D, Sharp D. Regulation of the angiotensin type-1
receptor by antisense oligonucleotides occurs through an RNase H-type mechanism.
Brain Res Mol Brain Res 1999;65:23-33.
[219] Aldrian-Herrada G, Desarmenien MG, Orcel H, Boissin-Agasse L, Mery J, Brugidou J,
et al. A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when
coupled to a retro-inverso delivery peptide. The antisense activity depresses the target
mRNA and protein in magnocellular oxytocin neurons. Nucleic Acids Res 1998;26:
4910-16.
[220] Salmi P, Kela J, Good F, Wengel J, Wahlestedt C. Locked nucleic acids (LNA): a novel
and efficacious class of oligonucleotides for antisense knockdown in vivo . Soc Neurosci
1999;25:2003-11.
[221] Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol
Behav 1976;17:1031-6.
[222] Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML. Caspase-
2 mediates neuronal cell death induced by -amyloid. J Neurosci 2000;20:1386-92.
[223] Senechal Y, Larmet Y, Dev KK. Unraveling in vivo functions of amyloid precursor pro-
tein: insights from knockout and knockdown studies. Neurodegenerative Dis 2006;3:
134-47.
[224] Khasar SG, Gold MS, Levine JD. A tetrodotoxin-resistant sodium current mediates
inflammatory pain in the rat. Neurosci Lett 1998;256:17-20.
[225] Stone LS, Vulchanova L. The pain of antisense: in vivo application of antisense oligonu-
cleotides for functional genomics in pain and analgesia. Adv Drug Deliv Rev 2003;55:
1081-112.
[226] Sibille E, Sarnyai Z, Benjamin D, Ga J, Baker H, Toth M. Antisense inhibition of
5-hydroxytryptamine 2a receptor induces an antidepressant-like effect in mice. Mol
Pharmacol 1997;52:1056-63.
[227] Cohen O, Erb C, Ginzberg D, Pollak Y, Seidman S, Shoham S, et al. Neuronal overex-
pression of “readthrough” acetylcholinesterase is associated with antisense-suppressible
behavioral impairments. Mol Psychiatry 2002;7:874-85.
[228] Argov Z, McKee D, Agus S, Brawer S, Shlomowitz N, Yoseph OB, et al. Treatment
of human myasthenia gravis with oral antisense suppression of acetylcholinesterase.
Neurology 2007;69:699-700.
[229] Surmeier DJ, Eberwine J, Wilson CJ, Cao Y, Stefani A, Kitai ST. Dopamine receptor sub-
types colocalize in rat striatonigral neurons. Proc Natl Acad Sci USA 1992;89:10178-82.
[230] Standifer KM, Rossi GC, Pasternak GW. Differential blockade of opioid analgesia by
antisense oligodeoxynucleotides directed against various G protein alpha subunits. Mol
Pharmacol 1996;50:293-8.
[231] Ramalingam A, Hirai A, Thompson EA. Glucocorticoid inhibition of fibroblast prolif-
eration and regulation of the cyclin kinase inhibitor p21Cip1. Mol Endocrinol 1997;11:
577-86.
[232] Rogatsky I, Trowbridge JM, Garabedian MJ. Glucocorticoid receptor-mediated cell
cycle arrest is achieved through distinct cell-specific transcriptional regulatory mecha-
nisms. Mol Cell Biol 1997;17:3181-93.
[233] Cha HH, Cram EJ, Wang EC, Huang AJ, Kasler HG, Firestone GL. Glucocorticoids
stimulate p21 gene expression by targeting multiple transcriptional elements within a ste-
roid responsive region of the p21waf1/cip1 promoter in rat hepatoma cells. J Biol Chem
1998;273:1998-2007.
[234] Bennett CF. Regulation of the immune response with antisense oligonucleotides.
Antisense Nucleic Acid Drug Dev 1999;9:423-7.